CIT-话题@MedSci

#CIT#

176篇内容 | 3529人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1738592, encodeId=c3b01e38592b7, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Clin Cancer Res：JAK1抑制剂Itacitinib可有效预防CAR T细胞疗法引发的细胞因子释放综合征, objectType=article, longId=204517, objectId=6bae20451ef6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bae20451ef6, replyNumber=0, likeNumber=89, createdTime=2021-06-27, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bae20451ef6, moduleTitle=Clin Cancer Res：JAK1抑制剂Itacitinib可有效预防CAR T细胞疗法引发的细胞因子释放综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bae20451ef6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738600, encodeId=b45f1e3860016, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=NEJM：ADC药物Sacituzumab govitecan一线治疗转移性三阴性乳腺癌, objectType=article, longId=210410, objectId=eb7421041030, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb7421041030, replyNumber=0, likeNumber=95, createdTime=2022-02-26, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb7421041030, moduleTitle=NEJM：ADC药物Sacituzumab govitecan一线治疗转移性三阴性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb7421041030)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738598, encodeId=d66f1e38598c3, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=NEJM：Upadacitinib治疗银屑病关节炎疗效优于阿达木单抗, objectType=article, longId=209559, objectId=afa5209559ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afa5209559ff, replyNumber=0, likeNumber=87, createdTime=2021-08-13, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afa5209559ff, moduleTitle=NEJM：Upadacitinib治疗银屑病关节炎疗效优于阿达木单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afa5209559ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738581, encodeId=3c021e3858197, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Gastroenterology：Upadacitinib治疗中重度克罗恩病II期临床获得成功, objectType=article, longId=196772, objectId=914c196e721f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=914c196e721f, replyNumber=0, likeNumber=90, createdTime=2020-09-05, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=914c196e721f, moduleTitle=Gastroenterology：Upadacitinib治疗中重度克罗恩病II期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=914c196e721f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738583, encodeId=f2c31e38583b4, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=FDA批准Onureg（azacitidine）治疗急性髓细胞性白血病（AML）, objectType=article, longId=200392, objectId=7b192003927b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b192003927b, replyNumber=0, likeNumber=68, createdTime=2021-02-15, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b192003927b, moduleTitle=FDA批准Onureg（azacitidine）治疗急性髓细胞性白血病（AML）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b192003927b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738596, encodeId=aaaf1e3859633, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=NEJM：瑞德西韦联合baricitinib治疗新冠患者, objectType=article, longId=207921, objectId=76ea20e921c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76ea20e921c1, replyNumber=0, likeNumber=67, createdTime=2021-12-27, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76ea20e921c1, moduleTitle=NEJM：瑞德西韦联合baricitinib治疗新冠患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76ea20e921c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738579, encodeId=09051e38579e3, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Elsevier的影响因子CiteScore正式公布！速看20分以上期刊, objectType=article, longId=196405, objectId=ede8196405f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ede8196405f8, replyNumber=0, likeNumber=104, createdTime=2021-01-17, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ede8196405f8, moduleTitle=Elsevier的影响因子CiteScore正式公布！速看20分以上期刊, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ede8196405f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738593, encodeId=c4a91e38593ce, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=欧洲监管机构对Sogroya（somapacitan）治疗成人生长激素缺乏症持积极意见, objectType=article, longId=206440, objectId=319320644031, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=319320644031, replyNumber=0, likeNumber=83, createdTime=2021-10-10, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=319320644031, moduleTitle=欧洲监管机构对Sogroya（somapacitan）治疗成人生长激素缺乏症持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=319320644031)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738584, encodeId=026f1e385849c, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=轻轻松松掌握文献知识图谱，发现科研创新思路——CiteSpace, objectType=article, longId=200626, objectId=b4b12006261d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4b12006261d, replyNumber=0, likeNumber=93, createdTime=2020-10-30, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4b12006261d, moduleTitle=轻轻松松掌握文献知识图谱，发现科研创新思路——CiteSpace, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4b12006261d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738594, encodeId=ca371e3859484, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=CiteScore可能成为新的期刊影响因子标准, objectType=article, longId=207259, objectId=67c720e259d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67c720e259d5, replyNumber=0, likeNumber=64, createdTime=2021-10-31, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67c720e259d5, moduleTitle=CiteScore可能成为新的期刊影响因子标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67c720e259d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738590, encodeId=f1681e38590fe, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Abrocitinib治疗中重度特应性皮炎的III期研究：已达到主要终点, objectType=article, longId=203284, objectId=ffda20328428, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffda20328428, replyNumber=0, likeNumber=75, createdTime=2020-12-12, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffda20328428, moduleTitle=Abrocitinib治疗中重度特应性皮炎的III期研究：已达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffda20328428)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738585, encodeId=d65e1e38585c5, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=NEJM：Upadacitinib治疗生物药难治性类风湿关节炎, objectType=article, longId=202158, objectId=6b4b202158b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b4b202158b8, replyNumber=0, likeNumber=71, createdTime=2021-03-09, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b4b202158b8, moduleTitle=NEJM：Upadacitinib治疗生物药难治性类风湿关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b4b202158b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738573, encodeId=e5f51e38573e9, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=III期JADE Compare试验：JAK1抑制剂abrocitinib治疗特应性皮炎取得积极结果, objectType=article, longId=190430, objectId=bffb1904303e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bffb1904303e, replyNumber=0, likeNumber=81, createdTime=2020-12-24, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bffb1904303e, moduleTitle=III期JADE Compare试验：JAK1抑制剂abrocitinib治疗特应性皮炎取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bffb1904303e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738582, encodeId=f7fe1e38582cd, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Lancet：abrocitinib单药用于中重度特应性皮炎的治疗, objectType=article, longId=198029, objectId=d78c19802962, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d78c19802962, replyNumber=0, likeNumber=57, createdTime=2020-08-16, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d78c19802962, moduleTitle=Lancet：abrocitinib单药用于中重度特应性皮炎的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d78c19802962)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738586, encodeId=65701e38586da, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=关节炎药物JAK抑制剂Baricitinib治疗斑秃：患者获得显著改善, objectType=article, longId=202774, objectId=0f2d202e740f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f2d202e740f, replyNumber=0, likeNumber=131, createdTime=2021-06-22, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f2d202e740f, moduleTitle=关节炎药物JAK抑制剂Baricitinib治疗斑秃：患者获得显著改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f2d202e740f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738591, encodeId=6bb31e3859130, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Science Advances：JAK抑制剂Baricitinib将新冠COVID-19患者死亡率降低71%, objectType=article, longId=203491, objectId=bf832034914b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf832034914b, replyNumber=0, likeNumber=56, createdTime=2021-07-02, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf832034914b, moduleTitle=Science Advances：JAK抑制剂Baricitinib将新冠COVID-19患者死亡率降低71%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf832034914b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738577, encodeId=cf201e38577d8, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Arthritis Rheumatol：新型JAK3/TEC抑制剂PF-06651600（ritlecitinib）对中重度类风湿性关节炎的疗效和安全性, objectType=article, longId=194372, objectId=d9c31943e212, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9c31943e212, replyNumber=0, likeNumber=84, createdTime=2020-07-22, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9c31943e212, moduleTitle=Arthritis Rheumatol：新型JAK3/TEC抑制剂PF-06651600（ritlecitinib）对中重度类风湿性关节炎的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9c31943e212)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738588, encodeId=a11a1e38588a1, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=EADV 2020：JAK抑制剂Baricitinib治疗湿疹，展现长期疗效和安全性, objectType=article, longId=202999, objectId=8918202999cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8918202999cd, replyNumber=0, likeNumber=60, createdTime=2021-02-13, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8918202999cd, moduleTitle=EADV 2020：JAK抑制剂Baricitinib治疗湿疹，展现长期疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8918202999cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738589, encodeId=9ad51e385899b, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=XELJANZ（tofacitinib）治疗强直性脊柱炎（AS）：III期研究取得阳性结果, objectType=article, longId=203133, objectId=529b20313392, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=529b20313392, replyNumber=0, likeNumber=75, createdTime=2021-06-29, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=529b20313392, moduleTitle=XELJANZ（tofacitinib）治疗强直性脊柱炎（AS）：III期研究取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=529b20313392)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1738575, encodeId=ed4c1e38575b5, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, objectTitle=Abcam荣获2020年CiteAb更佳抗体供应商奖, objectType=article, longId=190736, objectId=c87e190e365d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c87e190e365d, replyNumber=0, likeNumber=68, createdTime=2020-12-11, rootId=0, userName=12498877m109暂无昵称, userId=eabf34462441, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c87e190e365d, moduleTitle=Abcam荣获2020年CiteAb更佳抗体供应商奖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c87e190e365d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CIT

2020-05-29

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Clin Cancer Res：JAK1抑制剂Itacitinib可有效预防CAR T细胞疗法引发的细胞因子释放综合征

2021-06-27

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

NEJM：ADC药物Sacituzumab govitecan一线治疗转移性三阴性乳腺癌

2022-02-26

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

NEJM：Upadacitinib治疗银屑病关节炎疗效优于阿达木单抗

2021-08-13

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Gastroenterology：Upadacitinib治疗中重度克罗恩病II期临床获得成功

2020-09-05

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

FDA批准Onureg（azacitidine）治疗急性髓细胞性白血病（AML）

2021-02-15

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

NEJM：瑞德西韦联合baricitinib治疗新冠患者

2021-12-27

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Elsevier的影响因子CiteScore正式公布！速看20分以上期刊

2021-01-17

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

欧洲监管机构对Sogroya（somapacitan）治疗成人生长激素缺乏症持积极意见

2021-10-10

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

轻轻松松掌握文献知识图谱，发现科研创新思路——CiteSpace

2020-10-30

智智灵药 (审核中...)

前往app查看评论内容

#CIT#

CiteScore可能成为新的期刊影响因子标准

2021-10-31

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Abrocitinib治疗中重度特应性皮炎的III期研究：已达到主要终点

2020-12-12

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

NEJM：Upadacitinib治疗生物药难治性类风湿关节炎

2021-03-09

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

III期JADE Compare试验：JAK1抑制剂abrocitinib治疗特应性皮炎取得积极结果

2020-12-24

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Lancet：abrocitinib单药用于中重度特应性皮炎的治疗

2020-08-16

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

关节炎药物JAK抑制剂Baricitinib治疗斑秃：患者获得显著改善

2021-06-22

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Science Advances：JAK抑制剂Baricitinib将新冠COVID-19患者死亡率降低71%

2021-07-02

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Arthritis Rheumatol：新型JAK3/TEC抑制剂PF-06651600（ritlecitinib）对中重度类风湿性关节炎的疗效和安全性

2020-07-22

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

EADV 2020：JAK抑制剂Baricitinib治疗湿疹，展现长期疗效和安全性

2021-02-13

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

XELJANZ（tofacitinib）治疗强直性脊柱炎（AS）：III期研究取得阳性结果

2021-06-29

12498877m109暂无昵称 (审核中...)

前往app查看评论内容

#CIT#

Abcam荣获2020年CiteAb更佳抗体供应商奖

2020-12-11

科室
- - 订阅+
  - 更多科室
工具
服务